A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Phase of Trial: Phase III
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Febuxostat (Primary) ; Colchicine; Lansoprazole; Naproxen
- Indications Gout
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 13 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History